SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Art Vandelay AIA who wrote (3018)5/26/1999 6:33:00 AM
From: LLCF  Read Replies (1) | Respond to of 10280
 
<The factors are cost, convenience, and severity of allergy. IGE won't compete well buy these standards IMO.>

Thanks so much for commenting... I've been trying to follow the story, but this thread has become so busy it's tough... I see i'm creating spam as well, so I'll try and shut up.

DAK



To: Art Vandelay AIA who wrote (3018)5/26/1999 9:38:00 PM
From: Thomas M.  Respond to of 10280
 
Does anyone have a feel for how soon the Claritin/Zyrtec/Allegra group will become OTC (ballpark figure)?

Tom



To: Art Vandelay AIA who wrote (3018)5/27/1999 7:45:00 AM
From: John Bloxom  Respond to of 10280
 
I am advised that the IGE issue is not a problem because:

(a) monoclonal antibodies are difficult, and therefore expensive, to produce, raising popularity and reimbursement issues;

(b) they can be administered by injection only; and

(c) over time, they typically induce an immune response in the patient with the result that their efficacy erodes.

Just passing this along...

John


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News